Batch Reworking and Reprocessing

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

Biopharmaceutical Quality
The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.
Annual Product Review (APR) Product Quality Review (PQR)
Reprocessing Biotech Products
Stability data required by WHO-PQP Mercy Acquaye.
GMP Document and Record Retention
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
Quality control of raw materials In-process control
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
MANUFACTURING OF API AND INTERMEDIATES
Reference, Retention and Reserve Samples
Roles and Responsibilities
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
Sampling, Identification and Testing (S.I.T.). IntroductionIntroduction Define basic principles for applying sampling, identification and testing requirements.
Management of Quarantine and Reject Materials. Overview Introduction Scope Glossary Responsibilities The Requirements Introduction Scope Glossary Responsibilities.
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Management of Change Control. Overview Changes – Good or bad? Forced or voluntary? The Importance of Change Control Major Changes to both legacy company.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
1 GMP issues in Q assessment Wondiyfraw Worku Assessor 6 th CPH assessment training workshop, May 2014.
World Health Organization
QUALITY CONTROL OF PHYSICO-Chemical METHODS Introduction :Validation توثيق المصدوقية.
WHO Supplementary Training Modules GMP
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Radiopharmaceutical Production
© 2009 Michigan State University licensed under CC-BY-SA, original at Corrective Action.
Key changes and transition process
World Health Organization
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
World Health Organization
MB RESEARCH LABORATORIES Increased Regulatory Vigilance with respect to GLP Test Article Characterization George L. DeGeorge, Ph.D., DABT MB Research Laboratories.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
PRODUCT TRANSFER.
Changes without Prior Approval Breakout Session Summary Rick Smith Aventis Pasteur, Inc.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Important informations
Module 6 | Slide 1 of Contract Production and Analysis Section 7 Basic Principles of GMP.
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
Part 11, Electronic Records; Electronic Signatures
Basic Principles of GMP
Overview of FDA's Regulatory Framework for PET Drugs
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Validation | Slide 1 of 27 August 2006 Validation Supplementary Training Modules on Good Manufacturing Practice WHO Technical Report Series, No. 937, 2006.
Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.
Radiopharmaceutical Production
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
Pharmaceutical Quality Control & current Good Manufacturing Practice
ISO 9001:2015 Subject: Quality Management System Clause 8 - Operation
WORKSHOP ON ACCREDITATION OF BODIES CERTIFYING MEDICAL DEVICES INT MARKET TOPIC 9 CH 8 ISO MEASUREMENT, ANALYSIS AND IMPROVEMENT INTERNAL AUDITS.
Quality Control significance in pharmaceutical industry
1. Our Presentation Topic: Importance Of Validation & Qualification In Pharmaceutical Industries Presented By: Md. Tanjir Islam (Group C) 2.
In the name of God. Common Technical Document On Biotech.
Responsibilities of Sponsor, Investigator and Monitor
HOLD-TIME STUDIES.
BSB Biomanufacturing CHAPTER 4 GMP – Documentation Part I (SOP)
Radiopharmaceutical Production
World Health Organization
Responsibilities of Sponsor, Investigator and Monitor
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Quality Assurance and Quality Control in Generics
GMP Inspection Process
World Health Organization
Operationalizing Export Certification and Regionalization Programmes
Radiopharmaceutical Production
Radiopharmaceutical Production
Radiopharmaceutical Production
Presentation transcript:

Batch Reworking and Reprocessing

Contents Introduction Scope Glossary and Responsibilities General Requirements Specific Requirements on Reincorporation for Drug Products Specific Requirements for APIs (according to ICH Q7/ EU GMP Part II)

Introduction and Scope Introduction: All pharmaceutical manufacturing sites must implement a system designed to identify, document, investigate and control all activities of reprocessing/ reworking/ re-incorporation to ensure that quality, safety, purity and efficacy is maintained, and that the activities are in accordance with local and if applicable, corporate change control requirements. Scope: This training applies to all pharmaceutical manufacturing sites for APIs, Drug Product, medical devices and intermediates.

Glossary (1) Reworking: The rectification of a material/ product that does not conform to established standards or specifications using a process different from the established manufacturing process to obtain a compliant material/ product Reprocessing: The rectification of a material/product that does not conform to established standards or specifications, using method(s) that are part of the approved manufacturing process Re-incorporation: The introduction of a part of a batch within the specifications into another batch of the same product at a predetermined stage of the manufacturing process.

Responsibilities (1) Site Management and site Quality Management are responsible for ensuring that all reworking, reprocessing and re-incorporation are conducted according to company procedures, pertinent regulatory, GMP and Health, Safety and Environment (HSE) requirements Site Quality Management must approve all reworking, reprocessing and re-incorporation and all associated procedures/documents in relation to these operations before implementation.

Responsibilities (2) The Manufacturing Unit is responsible for carrying out reworking, reprocessing and re-incorporation when applicable, as defined and approved by site Quality Management Site Quality Management is responsible for ensuring that all reprocessing, reworking, and reincorporation activities are documented. (including the reasons).

General Requirements (1) Reworking or re-incorporation processes must be validated Concurrent validation is normally the best validation approach for reworking Reprocessing, reworking or re-incorporation of each material/product must be pre-authorized by site Quality Management through change control process after investigation of the potential quality impact and checking for compliance with regulatory requirements.

General Requirements (2) Any reprocessing, reworking or re-incorporation must be reviewed to determine if additional testing, stability studies, validation works or regulatory filings are required When reprocessing of a material/product within the established specifications and/or re-incorporation is/are often part of the routine manufacturing process, there must be appropriate documents established and applied for these operations (e.g. batch manufacturing records).

General Requirements (3) Reprocessing of an intermediate or an active pharmaceutical ingredient is acceptable: when it is a repetition of a chemical/physical operation, which is an integral part of the manufacturing process as described in the registration dossier Reprocessing when not part of the routine process and reworking of rejected finished products: must only be performed under exceptional circumstances.

General Requirements (4) These activities can only be performed if the finished product quality is not adversely affected by these operations and if the formula and specifications described in the registration dossiers are fully met Batches arising from these operations must be part of the stability program of the final product In addition, these steps must be considered to be part of the process validation.

General Requirements (5) Reprocessing and reworking processes that are not approved by authorities must be appropriately assessed and documented and informed to the authorities where applicable All batches resulting from reworking, reprocessing and/or re-incorporation activities must be fully traceable and reconciled In addition, traceability and reconciliation of all batches, which have been partly or completely reworked, reprocessed or reincorporated, must be also achieved in order to be able to know in which batch(es) these have been introduced.

General Requirements (6) Each reprocessing, reworking and reincorporation must be justified technically and this must be documented The reasons for performing these operations must also be documented.

Specific Requirements of Re-Incorporation for Drug Product (1) The maximum quantity, which can be reincorporated into another batch, must be specified and expressed as a percent in relation to the full production batch size The maximum number of partial batches that can be incorporated into one other batch must be limited and that maximum number determined on a case by case basis.

Specific Requirements of Re-Incorporation for Drug Product (2) Re-incorporation must be followed by a physical/ chemical operation in order to ensure homogeneity of the batch A shelf-life must be specified for the products to be reincorporated based on stability tests performed on bulk products at the given manufacturing step. Any batch of drug product which contains reincorporated material must not itself be re-incorporated into another batch of drug product.

Specific Requirements for APIs – Based on ICH Q7 (1) Intermediates and APIs failing to meet established specifications should be identified and quarantined These intermediates or APIs can be reprocessed or reworked as described in the following slides The final disposition of rejected materials should be recorded.

Specific Requirements for API Reprocessing – Based on ICH Q7 (2) If reprocessing is used for a majority of batches, such reprocessing should be included as part of the standard manufacturing process and should not be called reprocessing Introducing un-reacted material back into the process and repeating a chemical reaction is considered to be reprocessing unless it is part of an established process. Such reprocessing should be carefully evaluated that the quality is not adversely impacted due to the potential formation of by-products and over reacted materials.

API Reprocessing (1) Reprocessing in API manufacturing is generally acceptable But it should not be a routine process! Reprocessing normally improves the API quality There is a clear distinction between reprocessing and reworking.

API Reprocessing (2) In most cases reprocessing is related to a physical operation, such as: Crystallization Filtration Purification (Chromatography, Distillation) Drying Milling Typically if more than 10% of the batches have to be “reprocessed”, then the process should be checked for its robustness.

API Reprocessing (3) Reprocessing is Introducing an intermediate or API, including one that does not conform to standards and specifications, back into the process and repeating a crystallization step or other appropriate chemical or physical manipulation steps that are part of the established manufacturing process. Reprocessing is not Continuation of a process step after an in-process control test has shown that the initial step was incomplete.

API Reprocessing - Examples Re-crystallization from the same solvent Re-filtration through the same type of filter Re-milling using the same type of mill Introducing material to the process that conforms to specifications (e.g. tailings)

API Reprocessing – Process Validation The need of process validation for the reprocessing steps has to assessed and decided on a case by case basis Especially for biotech products and proteins process validation activities should be considered When the number of reprocessed batches is small, a concurrent validation approach should be used When reprocessing is performed routinely, reprocessing should be validated.

Is API Rework Different from Reprocessing? Yes, it is different However in former times, especially by FDA inspectors it was considered to be the same or similar FDA Definition in 1996: “Reprocessing is a system of reworking batches that do not conform to standards or specifications” Why is it different? Because it normally uses process conditions that are different from those of the original process.

API Rework – ICH Q7 Definition Subjecting an intermediate or API that does not conform to standards and specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API Therefore only non-conforming batches should be reworked And using processing steps different from the original process.

API Rework Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reason for non-conformance should be performed Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted, and documentation to show that the reworked product is of equivalent quality to that produced by the original process.

API Rework - Examples Re-crystallization from a different solvent Re-filtration through a finer sized filter Re-milling using a different type of mill Chromatography under different conditions Use of different drying device.

API Rework – Process Validation Validation of reworking procedures is critical and should clearly show that reworking does not adversely affect the quality or purity of the product (PIC/S Draft from April 1998) Concurrent validation is often the appropriate validation approach for rework procedures. This allows a protocol to define the rework procedure, how it will be carried out, and the expected results. If there is only one batch to be reworked, then an interim report can be written and the batch released, once it is found to be acceptable.

API Rework – Recommendations Check the impurity profile of each reworked batch against batches manufactured by the established process Consider if additional analytical methods should be used to characterize the reworked batch Evaluate if stability studies are needed (normally accelerated studies) Estimate rework costs before you start (feasibility study) Rework should remain exceptional.

API Rework – Regulatory Aspects Reworking procedures require “Prior Approval” from the Authorities unless potential reworking processes were described in the original submission (MAA, NDA, DMF, ASMF, etc.) Recommendation: File one or more rework procedures in the original dossiers whenever data from process development are available or create at least data on lab scale and submit Evaluate always, if rework is possible from regulatory viewpoint.

Summary of API Processing Reprocessing in API manufacturing is an acceptable way of treating materials that may not have met the specifications But it should not be performed routinely to cover-up intrinsic deficits in the process Reprocessing is normally covered by the existing filed procedures.

Summary of API Rework Rework in API manufacturing is an alternative way of treating materials that do not conform to specifications It should not be performed without investigation into the reasons of non-conformance and appropriate evaluation of the quality of the product reworked Reworking procedures normally require approval from Authorities.

Thank You Any Questions